Clinical Trial

A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

Enrolling by Invitation Phase 1
View on ClinicalTrials.gov →
Summary
Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: * Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN) * Characterize pharmacokinetics (PK) of NKX019 * Characterize immunogenicity of NKX019
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-19; most recent amendment 2026-06-17.
Status change: Suspended → Enrolling by Invitation 2026-06-17
Status change: Recruiting → Suspended 2026-04-16
Trial Details
NCT Number NCT06518668
Lead Sponsor Hospital for Special Surgery, New York
Collaborators: Nkarta, Inc.
Conditions Systemic Lupus Erythematosus
Enrollment 6 participants
Start Date 2024-07-01
Primary Completion 2026-12 (estimated)
Study Completion 2040-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-22